These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9669189)

  • 1. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
    Fischer P; Tauscher J; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
    Bouwer C; Stein DJ
    S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
    Landén M; Björling G; Agren H; Fahlén T
    J Clin Psychiatry; 1998 Dec; 59(12):664-8. PubMed ID: 9921700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
    Joffe RT; Schuller DR
    J Clin Psychiatry; 1993 Jul; 54(7):269-71. PubMed ID: 8335654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response.
    Blier P; Bergeron R; de Montigny C
    Neuropsychopharmacology; 1997 May; 16(5):333-8. PubMed ID: 9109104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone augmentation of antidepressant therapy.
    Dimitriou EC; Dimitriou CE
    J Clin Psychopharmacol; 1998 Dec; 18(6):465-9. PubMed ID: 9864079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible augmentation of antidepressant response by buspirone.
    Jacobsen FM
    J Clin Psychiatry; 1991 May; 52(5):217-20. PubMed ID: 2033029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic antidepressant augmentation.
    Sussman N
    J Clin Psychiatry; 1998; 59 Suppl 5():42-8; discussion 49-50. PubMed ID: 9635547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
    Gaynes BN; Farley JF; Dusetzina SB; Ellis AR; Hansen RA; Miller WC; Stürmer T
    Depress Anxiety; 2011 Nov; 28(11):989-98. PubMed ID: 21898717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation strategies to increase antidepressant efficacy.
    Shelton RC
    J Clin Psychiatry; 2007; 68 Suppl 10():18-22. PubMed ID: 17900205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases.
    Thomsen PH; Mikkelsen HU
    Eur Child Adolesc Psychiatry; 1999 Jun; 8(2):143-8. PubMed ID: 10435463
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of fluoxetine and buspirone for treatment-refractory depersonalization disorder.
    Abbas S; Chandra PS; Srivastava M
    J Clin Psychiatry; 1995 Oct; 56(10):484. PubMed ID: 7559376
    [No Abstract]   [Full Text] [Related]  

  • 15. Buspirone as an antidote to SSRI-induced bruxism in 4 cases.
    Bostwick JM; Jaffee MS
    J Clin Psychiatry; 1999 Dec; 60(12):857-60. PubMed ID: 10665633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
    Spigset O; Adielsson G
    Int Clin Psychopharmacol; 1997 Jan; 12(1):61-3. PubMed ID: 9179637
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.
    Robinson DS; Rickels K; Feighner J; Fabre LF; Gammans RE; Shrotriya RC; Alms DR; Andary JJ; Messina ME
    J Clin Psychopharmacol; 1990 Jun; 10(3 Suppl):67S-76S. PubMed ID: 2198303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: a case report.
    Sabuncuoglu O; Ekinci O; Berkem M
    Spec Care Dentist; 2009; 29(5):215-7. PubMed ID: 19740153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia'--1997, 12, 519-527.
    Lawlor B
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):496. PubMed ID: 9695043
    [No Abstract]   [Full Text] [Related]  

  • 20. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response.
    Papakostas GI; Chuzi SE; Sousa JL; Fava M
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):175-80. PubMed ID: 19641981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.